България - български - Изпълнителна агенция по лекарствата

dr. a. & l. schmidgall,wolfganggasse45-47, a-1121 viena - Други лекарства, студени комбинация, други актуални продукти за ставна и мускулна болка - oral drops, solution/cutaneous solution/inhalation vapour, solution

България - български - Изпълнителна агенция по лекарствата

orion corporation - Формотерол и други препарати за обструктивна заболявания на дихателните пътища - 160 micrograms/4,5 micrograms/inhalation, inhalation powder

България - български - Изпълнителна агенция по лекарствата

orion corporation - Формотерол и други препарати за обструктивна заболявания на дихателните пътища - 320 micrograms/9 micrograms/inhalation, inhalation powder

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - Меланомът - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Европейски съюз - български - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Европейски съюз - български - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - астма - Лекарства за обструктивна заболявания на дихателните пътища, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

България - български - Изпълнителна агенция по лекарствата

80 micrograms/4,5 micrograms/inhalation, inhalation powder

България - български - Изпълнителна агенция по лекарствата

80 micrograms/4,5 micrograms/inhalation, inhalation powder

България - български - Изпълнителна агенция по лекарствата

80 micrograms/4,5 micrograms/inhalation, inhalation powder

България - български - Изпълнителна агенция по лекарствата

320 micrograms/9 micrograms/inhalation, inhalation powder